17.12.2021 • News

Clariant Joins German Hydrogen Project

Clariant Catalysts is participating in Germany’s TransHyDE project AmmoRef, which aims to develop technologies and catalysts for ammonia cracking to facilitate future hydrogen transport.

Marvin Estenfelder, head of R&D at Clariant Catalysts, said the company has been involved in R&D and cross-industry collaborations in this area for many years and has already developed numerous catalysts for use in innovative hydrogen applications. “We are confident that together we will make it possible to recover pure hydrogen from ammonia in the scales required for efficient and safe mass transportation of hydrogen,” he said.

Although green hydrogen is an abundant and clean energy source, its high volatility and very low density make it difficult and expensive to transport. An economically viable method is to convert hydrogen to ammonia for transportation and release it at the point of use. The release is achieved by cracking (dissociation) of ammonia into hydrogen.

(c) Clariant
(c) Clariant

There are commercial processes and catalysts available currently, but at relatively high energy costs. AmmoRef aims to develop new catalysts and technologies for ammonia dissociation at lower energy costs and improved efficiency.

Clariant’s role is to develop new and improved generations of its existing ammonia cracking catalysts. It will be collaborating non-exclusively with industry partners BASF and ThyssenKrupp, as well as the Max Planck Institute and some German universities.

Author: Elaine Burridge, Freelance Journalist

Interview

Driving Transformation
Interconnected Global Chemicals Logistics

Driving Transformation

DP World is reshaping global chemical supply chains. Christene Smith of CHEManager interviews Markus Kanis, Global SVP Chemicals, on the company’s roadmap, new technologies, and the evolving demands of global trade.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read